Catalent (CTLT) Expands Its Facility Capabilities in Germany

Company Expansion - Catalent has completed the expansion of its clinical supply facility in Schorndorf, Germany, which is expected to enhance its capabilities in clinical trial supply materials and support its pharma and biotech customers [1][16] - The expansion includes the addition of temperature-controlled storage and a new fully automatic bottle-filling line, which will improve service levels and accommodate future customer needs [2][16] Market Potential - The global clinical trial supplies market is projected to grow from $3.9 billion in 2023 to$6.3 billion by 2028, reflecting a compound annual growth rate (CAGR) of 9.9%, driven by increased R&D spending and a rise in clinical trials [3] Financial Performance - Catalent's shares have increased by 24.8% over the past year, significantly outperforming the industry, which saw a decline of 2.2% [5] - The company reported year-over-year improvements in its fiscal Q3 2024 results, with revenue growth in the Pharma and Consumer Health segment, and an increase in adjusted EBITDA margin for the second consecutive quarter [10] Industry Outlook - The recent expansion is expected to provide a significant boost to Catalent's position in the clinical trials market, particularly in the European region [8]